<p>隨着美國股市在人工智能泡沫擔憂和主要指數波動的挑戰環境中航行，投資者密切關注就業數據和零售銷售等關鍵經濟指標，以評估未來趨勢。在這種環境下，擁有強大內部持股的成長型公司可以提供獨特的吸引力，因為高比例的內部持股通常表明對公司長期前景的信心，儘管市場波動較大。</p>
<h3>美國內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>超微計算機 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.9%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17.3%</td>
<td>78.5%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>133.2%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們篩選的 204 只內部持股比例高的快速成長美國公司的完整名單。</p>
<p>讓我們更仔細地看看我們從篩選公司中挑選的幾家公司。</p>
<h2>Bridgewater Bancshares (BWB)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Bridgewater Bancshares, Inc. 是 Bridgewater Bank 的銀行控股公司，在美國提供一系列銀行產品和服務，市值為 5.1749 億美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自其銀行業務部門，產生了 1.2724 億美元的收入。</p>
<p><strong>內部持股：</strong> 20.5%</p>
<p><strong>收益增長預測：</strong> 每年 22%。</p>
<p>Bridgewater Bancshares 展示了增長潛力，預計收益每年增長 22%，超過美國市場的平均水平。然而，內部持股動態顯示最近購買的股份多於出售的股份，表明儘管過去一個季度沒有實質性購買，但仍然對公司充滿信心。該公司交易價格顯著低於估計的公允價值，預計年收入增長為 14.4%。最近的領導層變動可能會增強信貸策略，並支持在商業貸款領域的進一步擴展。</p>
<ul>
<li>在我們的收益增長報告中更詳細地瞭解 Bridgewater Bancshares 的潛力。</li>
<li>我們最近的估值報告指出，Bridgewater Bancshares 的股票在市場上可能被低估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c54dff-423c-4c2d-8fc1-01efaa0a244d/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c54dff-423c-4c2d-8fc1-01efaa0a244d/chart/ownership-breakdown"/></p>
<p>截至 2025 年 12 月的 BWB 持股分佈</p>
<h2>Aebi Schmidt Holding (AEBI)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Aebi Schmidt Holding AG 開發和製造特種車輛及附件，市值為 10.4 億美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自北美，貢獻了 7.8105 億美元，歐洲及其他地區貢獻了 5.1543 億美元。</p>
<p><strong>內部持股：</strong> 14.2%</p>
<p><strong>收益增長預測：</strong> 每年 148.1%。</p>
<p>Aebi Schmidt Holding 正在經歷顯著增長，預計收益每年增長 148.1%，超過美國市場。內部活動顯示過去三個月有大量購買，表明對其發展軌跡的信心。儘管交易價格低於估計公允價值 62%，且強勁的收入增長預測為 29.3%，但最近的財務數據顯示，與去年相比，利潤率和淨收入下降，表明在快速擴張過程中維持盈利能力面臨挑戰。</p>
<ul>
<li>點擊這裏瞭解 Aebi Schmidt Holding 的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>我們精心準備的 Aebi Schmidt Holding 估值報告暗示其股價可能過高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9ad44c93-884f-42b4-b627-e0de80a5b732/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9ad44c93-884f-42b4-b627-e0de80a5b732/chart/ownership-breakdown"/></p>
<p>截至 2025 年 12 月的 AEBI 持股分佈</p>
<h2>Precigen (PGEN)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Precigen, Inc. 是一家發現和臨牀階段的生物製藥公司，專注於開發用於免疫腫瘤學、自身免疫疾病和傳染病的基因和細胞療法，市值為 13.5 億美元。</p>
<p><strong>運營：</strong> 公司的收入部門專注於開發先進的基因和細胞療法，旨在治療免疫腫瘤學、自身免疫疾病和傳染病。</p>
<p><strong>內部持股：</strong> 12.3%</p>
<p><strong>收益增長預測：</strong> 每年 79.7%。</p>
<p>Precigen 的收入預計每年增長 55.8%，顯著超過美國市場，同時計劃在三年內實現盈利。儘管最近內部出售和高股價波動，PAPZIMEOS™ 的 FDA 批准標誌着在治療複發性呼吸道乳頭狀瘤病方面的重大進展。然而，最近的財務數據顯示，儘管收入增長，淨虧損卻有所增加，突顯在擴張和創新努力中實現盈利的持續挑戰。</p>
<ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 Precigen 的表現。</li>
<li>在審查我們最新的估值報告後，Precigen 的股價可能過於樂觀。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 PGEN 收益和收入增長</p>
<h2>總結</h2>
<ul>
<li>在這裏探索我們篩選的 204 個內部持股比例高的快速成長美國公司。</li>
<li>準備好進入其他投資風格了嗎？人工智能即將改變醫療保健。這 30 只股票正在從早期診斷到藥物發現方面進行工作。最重要的是——它們的市值都在 100 億美元以下——仍然有機會提前佈局。</li>
</ul>
<p>這篇來自 Simply Wall St 的文章是一般性的。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖作為財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具如公司和/或信託實體間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</p>
<p>國防與災難的移動基礎設施</p>
<p>下一波機器人技術不是類人機器人，而是能夠在 30 分鐘內在任何地方提供 5G、ISR 和雷達的完全自主塔。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>由 CiTech 贊助</p>

<p>這篇文章強調了具有強大內部持股的成長股，重點關注了 Bridgewater Bancshares、Aebi Schmidt Holding 和 Precigen。這些公司顯示出有前景的盈利增長預測，內部活動表明對其發展軌跡的信心。儘管市場波動，這些股票因其增長前景和內部持股而具有潛在價值。該分析基於歷史數據和預測，並非財務建議</p>

<p>As the U.S. stock market navigates a challenging landscape marked by AI bubble concerns and fluctuating major indexes, investors are keenly observing key economic indicators like employment data and retail sales to gauge future trends. In this environment, growth companies with strong insider ownership can offer a unique appeal, as high insider stakes often signal confidence in the company's long-term prospects despite broader market volatility.</p>
<div class="lb-trans"><p>隨着美國股市在人工智能泡沫擔憂和主要指數波動的挑戰環境中航行，投資者密切關注就業數據和零售銷售等關鍵經濟指標，以評估未來趨勢。在這種環境下，擁有強大內部持股的成長型公司可以提供獨特的吸引力，因為高比例的內部持股通常表明對公司長期前景的信心，儘管市場波動較大。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美國內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Super Micro Computer (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.9%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17.3%</td>
<td>78.5%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>133.2%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>超微計算機 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.9%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17.3%</td>
<td>78.5%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>133.2%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 204 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們篩選的 204 只內部持股比例高的快速成長美國公司的完整名單。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>讓我們更仔細地看看我們從篩選公司中挑選的幾家公司。</p>
</div><h2>Bridgewater Bancshares (BWB)</h2>
<div class="lb-trans"><h2>Bridgewater Bancshares (BWB)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Bridgewater Bancshares, Inc. is the bank holding company for Bridgewater Bank, offering a range of banking products and services in the United States with a market cap of $517.49 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Bridgewater Bancshares, Inc. 是 Bridgewater Bank 的銀行控股公司，在美國提供一系列銀行產品和服務，市值為 5.1749 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its banking segment, which generated $127.24 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其銀行業務部門，產生了 1.2724 億美元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 20.5%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 20.5%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 22% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 22%。</p>
</div><p>Bridgewater Bancshares demonstrates growth potential with its earnings forecast to grow 22% annually, surpassing the US market's average. However, insider ownership dynamics show more shares were bought than sold recently, indicating confidence despite no substantial buying in the past quarter. The company trades at a significant discount to estimated fair value and expects revenue growth of 14.4% annually. Recent leadership changes could bolster credit strategies and support further expansion in commercial lending sectors.</p>
<div class="lb-trans"><p>Bridgewater Bancshares 展示了增長潛力，預計收益每年增長 22%，超過美國市場的平均水平。然而，內部持股動態顯示最近購買的股份多於出售的股份，表明儘管過去一個季度沒有實質性購買，但仍然對公司充滿信心。該公司交易價格顯著低於估計的公允價值，預計年收入增長為 14.4%。最近的領導層變動可能會增強信貸策略，並支持在商業貸款領域的進一步擴展。</p>
</div><ul>
<li>Take a closer look at Bridgewater Bancshares' potential here in our earnings growth report.</li>
<li>Insights from our recent valuation report point to the potential undervaluation of Bridgewater Bancshares shares in the market.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的收益增長報告中更詳細地瞭解 Bridgewater Bancshares 的潛力。</li>
<li>我們最近的估值報告指出，Bridgewater Bancshares 的股票在市場上可能被低估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c54dff-423c-4c2d-8fc1-01efaa0a244d/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/49c54dff-423c-4c2d-8fc1-01efaa0a244d/chart/ownership-breakdown"/></p>
<p>BWB Ownership Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 BWB 持股分佈</p>
</div><h2>Aebi Schmidt Holding (AEBI)</h2>
<div class="lb-trans"><h2>Aebi Schmidt Holding (AEBI)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Aebi Schmidt Holding AG develops and manufactures special-purpose vehicles and attachments, with a market cap of $1.04 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aebi Schmidt Holding AG 開發和製造特種車輛及附件，市值為 10.4 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from North America, contributing $781.05 million, and Europe and the Rest of the World, accounting for $515.43 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自北美，貢獻了 7.8105 億美元，歐洲及其他地區貢獻了 5.1543 億美元。</p>
</div><p><strong>Insider Ownership:</strong> 14.2%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 14.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 148.1% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 148.1%。</p>
</div><p>Aebi Schmidt Holding is experiencing significant growth with earnings forecast to rise 148.1% annually, outpacing the US market. Insider activity shows substantial buying over the past three months, signaling confidence in its trajectory. Despite trading at 62% below estimated fair value and strong revenue growth projections of 29.3%, recent financials reveal declining profit margins and net income compared to last year, suggesting challenges in maintaining profitability amidst rapid expansion efforts.</p>
<div class="lb-trans"><p>Aebi Schmidt Holding 正在經歷顯著增長，預計收益每年增長 148.1%，超過美國市場。內部活動顯示過去三個月有大量購買，表明對其發展軌跡的信心。儘管交易價格低於估計公允價值 62%，且強勁的收入增長預測為 29.3%，但最近的財務數據顯示，與去年相比，利潤率和淨收入下降，表明在快速擴張過程中維持盈利能力面臨挑戰。</p>
</div><ul>
<li>Click here to discover the nuances of Aebi Schmidt Holding with our detailed analytical future growth report.</li>
<li>Our expertly prepared valuation report Aebi Schmidt Holding implies its share price may be too high.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解 Aebi Schmidt Holding 的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>我們精心準備的 Aebi Schmidt Holding 估值報告暗示其股價可能過高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9ad44c93-884f-42b4-b627-e0de80a5b732/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/9ad44c93-884f-42b4-b627-e0de80a5b732/chart/ownership-breakdown"/></p>
<p>AEBI Ownership Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 AEBI 持股分佈</p>
</div><h2>Precigen (PGEN)</h2>
<div class="lb-trans"><h2>Precigen (PGEN)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of $1.35 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Precigen, Inc. 是一家發現和臨牀階段的生物製藥公司，專注於開發用於免疫腫瘤學、自身免疫疾病和傳染病的基因和細胞療法，市值為 13.5 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segments focus on developing advanced gene and cell therapies aimed at treating conditions in immuno-oncology, autoimmune disorders, and infectious diseases.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入部門專注於開發先進的基因和細胞療法，旨在治療免疫腫瘤學、自身免疫疾病和傳染病。</p>
</div><p><strong>Insider Ownership:</strong> 12.3%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 12.3%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 79.7% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 79.7%。</p>
</div><p>Precigen's revenue is forecast to grow 55.8% annually, significantly outpacing the US market, while it aims for profitability within three years. Despite recent insider selling and high share price volatility, the FDA approval of PAPZIMEOS™ marks a pivotal advancement in treating recurrent respiratory papillomatosis. However, recent financials show increased net losses despite revenue growth, highlighting ongoing challenges in achieving profitability amidst its expansion and innovation efforts.</p>
<div class="lb-trans"><p>Precigen 的收入預計每年增長 55.8%，顯著超過美國市場，同時計劃在三年內實現盈利。儘管最近內部出售和高股價波動，PAPZIMEOS™ 的 FDA 批准標誌着在治療複發性呼吸道乳頭狀瘤病方面的重大進展。然而，最近的財務數據顯示，儘管收入增長，淨虧損卻有所增加，突顯在擴張和創新努力中實現盈利的持續挑戰。</p>
</div><ul>
<li>Get an in-depth perspective on Precigen's performance by reading our analyst estimates report here.</li>
<li>Upon reviewing our latest valuation report, Precigen's share price might be too optimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 Precigen 的表現。</li>
<li>在審查我們最新的估值報告後，Precigen 的股價可能過於樂觀。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/earnings-and-revenue-growth"/></p>
<p>PGEN Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 PGEN 收益和收入增長</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Explore the 204 names from our Fast Growing US Companies With High Insider Ownership screener here.</li>
<li>Ready To Venture Into Other Investment Styles? AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏探索我們篩選的 204 個內部持股比例高的快速成長美國公司。</li>
<li>準備好進入其他投資風格了嗎？人工智能即將改變醫療保健。這 30 只股票正在從早期診斷到藥物發現方面進行工作。最重要的是——它們的市值都在 100 億美元以下——仍然有機會提前佈局。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p>這篇來自 Simply Wall St 的文章是一般性的。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖作為財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具如公司和/或信託實體間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>國防與災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人機器人，而是能夠在 30 分鐘內在任何地方提供 5G、ISR 和雷達的完全自主塔。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 贊助</p>
</div>

聚焦 Bridgewater Bancshares 及其他兩隻內部持股強勁的成長型股票